Search Results

Company to host a webcast   today at 8:30 a.m. Medical Affairs: Building Medical Affairs capabilities to expand education and physician support activities to ensure optimal medical impact including continued clinical publications involving ANAVEX®2-73 and projected in any of such statements due to various factors, including the risks set forth in the Company’s most Barwicki Investor Relations Tel: 516-662-9461 Email: andrew@barwicki.com [1]  https://www.braincouncil.eu

In 2020, Alzheimer's and other dementias cost the nation $305 billion. By 2050, these costs could rise as high as $1.1 trillion.[5] There are currently over 50 million people Alzheimer's & Dementia: Translational Research & Clinical Interventions, 6(1), e12013. [5] https://www.nia.nih.gov /health/alzheimers; https://www.alz.org/alzheimers-dementia/facts-figures. [6] Alzheimer's Disease International World Alzheimer Report 2019. https://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf. [7] AARP. 2020

have found a new drug is up to four times more effective at treating Alzheimer’s disease than existing medication

We are grateful to the dedication from participants, their families, and the sites for taking part in 2030, according to the European Brain Council. [ 3]  The World Health Organization (WHO) estimated the cost care, medicines, diagnostics, informal caregiver time, community services and long-term care facility costs (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics Alzheimers Dement. 2024;20(5):3352-3363. doi:10.1002/alz.13770  [3] https://www.braincouncil.eu/projects

Most people experience their first symptoms of MS between the ages of 20 and 40. Currently there is no cure for MS and many medications have serious side effects and some carry significant (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media: and Biology Volume 964 (2017) Sigma Receptors: Their Role in Disease and as Therapeutic Targets. [4] https

In 2020, Alzheimer’s and other dementias cost the nation approximately $305 billion. By 2050, these costs could rise as high as $1.1 trillion.[18] There are currently over 50 million people Biology Volume 964 (2017) Sigma Receptors: Their Role in Disease and as Therapeutic Targets. [18] https ://www.nia.nih.gov/health/alzheimers ; https://www.alz.org/alzheimers-dementia/facts-figures ; [19] Alzheimer World Alzheimer Report 2019. https://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf . [20] AARP.

2030, according to the European Brain Council. [3] The World Health Organization (WHO) estimated the cost care, medicines, diagnostics, informal caregiver time, community services, and long-term care facility costs (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most PMID: 37251789; PMCID: PMC10220264. [3] https://www.braincouncil.eu/projects/rethinking-alzheimers-disease

precision medicine therapies to patients with devastating rare diseases, as well as the largest unmet medical Upon review of the most recent data, the DSMB made the recommendation to continue the study without modification Conference Call / Webcast Information The live webcast of the conference call can be accessed online at http projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media:

blarcamesine ) is an oral formulation, study participants are able to receive shipments of their study medication Conference Call / Webcast Information Anavex will host a conference call and webcast today at 4:30 p.m The live webcast of the conference call can be accessed online at http://www.wsw.com/webcast/cc/avxl13 projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media:

nervous system (CNS) disorders, today announced the peer-reviewed publication in American Journal of Medical The paper can be accessed online at: https://onlinelibrary.wiley.com/doi/10.1002/ajmg.a.62853 Anavex Autism spectrum disorder is a behavioral diagnosis while Fragile X Syndrome is a medical/genetic diagnosis Barwicki Investor Relations Tel: 516-662-9461 Email: andrew@barwicki.com [1] https://fragilex.org/understanding-fragile-x /fragile-x-101/prevalence/ [2] https://www.nature.com/articles/s41598-021-94079-7 [3] Advances in Experimental

A webcast is available to clients of the firm at https://hcwevents.com/ . H.C. A webcast is available to clients of the firm at https://hcwevents.com/ . (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most

live webcast including audio and slides and subsequent archived replay presentation can be accessed at http ://wsw.com/webcast/jeff105/avxl or via the investor material page of the Company’s website at https:/ (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated ongoing Anavex corporate communications, please click on the following link to join our email alert list: https Dobson Media Group 203-258-0159 dennisdobsonjr@dobsonmediagroup.com Social Media: Bill Douglass Gotham